Cargando…

Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial

BACKGROUND: Pharmacologic treatment options for posttraumatic stress disorder (PTSD) are limited in number and effectiveness. Medications currently in use to treat PTSD were originally approved based on their efficacy in other disorders, such as major depression. Substantial research in PTSD suggest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dunlop, Boadie W, Rothbaum, Barbara O, Binder, Elisabeth B, Duncan, Erica, Harvey, Philip D, Jovanovic, Tanja, Kelley, Mary E, Kinkead, Becky, Kutner, Michael, Iosifescu, Dan V, Mathew, Sanjay J, Neylan, Thomas C, Kilts, Clinton D, Nemeroff, Charles B, Mayberg, Helen S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082482/ https://www.ncbi.nlm.nih.gov/pubmed/24950747 http://dx.doi.org/10.1186/1745-6215-15-240

Ejemplares similares

DNA methylation levels are associated with CRF(1) receptor antagonist treatment outcome in women with post-traumatic stress disorder
por: Pape, Julius C., et al.
Publicado: (2018)

Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial
por: Dunlop, Boadie W, et al.
Publicado: (2012)

Assessing Treatment-Resistant Posttraumatic Stress Disorder: The Emory Treatment Resistance Interview for PTSD (E-TRIP)
por: Dunlop, Boadie W., et al.
Publicado: (2014)

Combined effects of genotype and childhood adversity shape variability of DNA methylation across age
por: Czamara, Darina, et al.
Publicado: (2021)

Neuroimaging-based biomarkers for treatment selection in major depressive disorder
por: Dunlop, Boadie W., et al.
Publicado: (2014)

Neuroimaging Advances for Depression
por: Dunlop, Boadie W., et al.
Publicado: (2017)

The United States index of socioeconomic deprivation for individuals (USiDep)
por: Dunlop, Boadie W., et al.
Publicado: (2022)

Posttraumatic Stress Disorder Increases Sensitivity to Long Term Losses among Patients with Major Depressive Disorder
por: Engelmann, Jan B., et al.
Publicado: (2013)

Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators
por: Lamon-Fava, Stefania, et al.
Publicado: (2023)

Individuals with depression exhibiting a pro-inflammatory phenotype receiving omega-3 polyunsaturated fatty acids experience improved motivation-related cognitive function: Preliminary results from a randomized controlled trial
por: Mac Giollabhui, Naoise, et al.
Publicado: (2023)

CORTICOTROPINS (ACTH) : X. BIOLOGICAL INVESTIGATIONS ONα-CORTICOTROPIN
por: Li, Choh Hao, et al.
Publicado: (1957)

Tailoring therapeutic strategies for treating posttraumatic stress disorder symptom clusters
por: Norrholm, Seth D, et al.
Publicado: (2010)

Treatment-Specific Hippocampal Subfield Volume Changes With Antidepressant Medication or Cognitive-Behavior Therapy in Treatment-Naive Depression
por: Tai, Hua-Hsin, et al.
Publicado: (2021)

l-DOPA and consolidation of fear extinction learning among women with posttraumatic stress disorder
por: Cisler, Josh M., et al.
Publicado: (2020)

Common genes associated with antidepressant response in mouse and man identify key role of glucocorticoid receptor sensitivity
por: Carrillo-Roa, Tania, et al.
Publicado: (2017)

Sex Differences in Peritraumatic Inflammatory Cytokines and Steroid Hormones Contribute to Prospective Risk for Nonremitting Posttraumatic Stress Disorder
por: Lalonde, Chloe S., et al.
Publicado: (2021)

Early Life Stress Associated With Increased Striatal N-Acetyl-Aspartate: Cerebrospinal Fluid Corticotropin-Releasing Factor Concentrations, Hippocampal Volume, Body Mass, and Behavioral Correlates
por: Coplan, Jeremy D., et al.
Publicado: (2018)

Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults
por: Polychroniou, Philip E., et al.
Publicado: (2018)

Modes of Large-Scale Brain Network Organization during Threat Processing and Posttraumatic Stress Disorder Symptom Reduction during TF-CBT among Adolescent Girls
por: Cisler, Josh M., et al.
Publicado: (2016)

Beyond the bins: interpreting and discussing pharmacogenomic reports with psychiatric patients
por: Dunlop, Boadie W.
Publicado: (2020)

Neural Mechanisms of Impaired Fear Inhibition in Posttraumatic Stress Disorder
por: Jovanovic, Tanja, et al.
Publicado: (2011)

Enhancing exposure therapy for posttraumatic stress disorder (PTSD): a randomized clinical trial of virtual reality and imaginal exposure with a cognitive enhancer
por: Difede, JoAnn, et al.
Publicado: (2022)

Neurobiological findings in posttraumatic stress disorder: a review
por: Vedantham, Kumar, et al.
Publicado: (2000)

A test of affect processing bias in response to affect regulation
por: Bush, Keith A., et al.
Publicado: (2022)

Beyond depression and anxiety; a systematic review about the role of corticotropin-releasing hormone antagonists in diseases of the pelvic and abdominal organs
por: Pagán-Busigó, Joshua E., et al.
Publicado: (2022)

A Virtual Standardized Patient–Based Assessment Tool to Evaluate Psychiatric Residents’ Psychopharmacology Proficiency
por: Rakofsky, Jeffrey J., et al.
Publicado: (2020)

Effects of oxytocin on prosocial behavior and the associated profiles of oxytocinergic and corticotropin-releasing hormone receptors in a rodent model of posttraumatic stress disorder
por: Wang, Sheng-Chiang, et al.
Publicado: (2019)

Residues remote from the binding pocket control the antagonist selectivity towards the corticotropin-releasing factor receptor-1
por: Sun, Xianqiang, et al.
Publicado: (2015)

Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis
por: Busch, Howard, et al.
Publicado: (2022)

Pharmacophore Modelling and 3D-QSAR Studies on N(3)-Phenylpyrazinones as Corticotropin-Releasing Factor 1 Receptor Antagonists
por: Kaur, Paramjit, et al.
Publicado: (2012)

Performance of the Adult ADHD Self-Report Scale-v1.1 in Adults with Major Depressive Disorder
por: Dunlop, Boadie W., et al.
Publicado: (2018)

Preliminary Evidence of Increased Hippocampal Myelin Content in Veterans with Posttraumatic Stress Disorder
por: Chao, Linda L., et al.
Publicado: (2015)

Psychotherapy or medication for depression? Using individual symptom meta-analyses to derive a Symptom-Oriented Therapy (SOrT) metric for a personalised psychiatry
por: Kappelmann, Nils, et al.
Publicado: (2020)

Feasibility of Identifying Eligible Trauma Patients for Posttraumatic Stress Disorder Intervention
por: Malcoun, Emily, et al.
Publicado: (2010)

Structure-based drug discovery of a corticotropin-releasing hormone receptor 1 antagonist using an X-ray free-electron laser
por: Kim, Hoyoung, et al.
Publicado: (2023)

Prior trauma exposure, posttraumatic stress symptoms, and COVID-19 vaccine hesitancy
por: Nishimi, Kristen, et al.
Publicado: (2022)

Differential Genetic and Epigenetic Regulation of catechol-O-methyltransferase is Associated with Impaired Fear Inhibition in Posttraumatic Stress Disorder
por: Norrholm, Seth Davin, et al.
Publicado: (2013)

Lessons learned: A neuroimaging research center's transition to open and reproducible science
por: Bush, Keith A., et al.
Publicado: (2022)

Corticotropin and Cortisone in Diseases of the Nervous System
por: Merritt, H. Houston
Publicado: (1952)

Is there any place to corticotropin test in sepsis?
por: Abdellatif, S, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_lqkh33kh4udtltjg6ri47qpknm